Release Date: 23/03/12 20:23 Summary: Becoming a substantial holder in MMX by DB Group -Schedule 2 Price Sensitive: No Download Document 1.06MB Download
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling